Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Tcr2 Therapeutics stock

Learn how to easily invest in Tcr2 Therapeutics stock.

Tcr2 Therapeutics Inc is a biotechnology business based in the US. Tcr2 Therapeutics shares (TCRR) are listed on the NASDAQ and all prices are listed in US Dollars. Tcr2 Therapeutics employs 145 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Tcr2 Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TCRR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Tcr2 Therapeutics stock price (NASDAQ: TCRR)

Use our graph to track the performance of TCRR stocks over time.

Tcr2 Therapeutics shares at a glance

Information last updated 2022-06-25.
Latest market close$2.94
52-week range$2.07 - $19.03
50-day moving average $2.41
200-day moving average $4.65
Wall St. target price$13.89
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.81

Buy Tcr2 Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
$0
$0
N/A
Financial advice powered by relationships, not commissions.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Tcr2 Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tcr2 Therapeutics price performance over time

Historical closes compared with the close of $2.94 from 2022-06-29

1 week (2022-06-23) 4.63%
1 month (2022-05-26) N/A
3 months (2022-03-30) 10.53%
6 months (2021-12-30) -38.62%
1 year (2021-06-30) -82.08%
2 years (2020-06-30) -80.86%
3 years (2019-06-28) 14.31
5 years (2017-06-26) N/A

Tcr2 Therapeutics financials

Gross profit TTM $0
Return on assets TTM -17.96%
Return on equity TTM -35.51%
Profit margin 0%
Book value $6.62
Market capitalisation $110.2 million

TTM: trailing 12 months

Tcr2 Therapeutics share dividends

We're not expecting Tcr2 Therapeutics to pay a dividend over the next 12 months.

Tcr2 Therapeutics share price volatility

Over the last 12 months, Tcr2 Therapeutics's shares have ranged in value from as little as $2.065 up to $19.03. A popular way to gauge a stock's volatility is its "beta".

TCRR.US volatility(beta: 2.2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tcr2 Therapeutics's is 2.197. This would suggest that Tcr2 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Tcr2 Therapeutics overview

TCR2 Therapeutics Inc. , a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016.

Frequently asked questions

What percentage of Tcr2 Therapeutics is owned by insiders or institutions?
Currently 0.891% of Tcr2 Therapeutics shares are held by insiders and 75.455% by institutions.
How many people work for Tcr2 Therapeutics?
Latest data suggests 145 work at Tcr2 Therapeutics.
When does the fiscal year end for Tcr2 Therapeutics?
Tcr2 Therapeutics's fiscal year ends in December.
Where is Tcr2 Therapeutics based?
Tcr2 Therapeutics's address is: 100 Binney Street, Cambridge, MA, United States, 02142
What is Tcr2 Therapeutics's ISIN number?
Tcr2 Therapeutics's international securities identification number is: US87808K1060
What is Tcr2 Therapeutics's CUSIP number?
Tcr2 Therapeutics's Committee on Uniform Securities Identification Procedures number is: 87808K106

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site